This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
West NJ . Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 1997; 17: 696–706.
Seber A, Shu XO, Defor T, Sencer S, Ramsay N . Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 1999; 23: 35–40.
Roberts HR, Monroe DM, White GC . The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858–3864.
Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D . Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405–407.
Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E . Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2004; 2: 1853–1855.
Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935–1944.
Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216–4223.
Williams JR . The fibrinolytic activity of urine. Br J Exp Pathol 1951; 32: 530–537.
Coggins JT, Allen TD . Insoluble fibrin clots within the urinary tract as a consequence of epsilon aminocaprioic acid therapy. J Urol 1972; 107: 647–649.
Acknowledgements
The study was funded by NovoNordisk Pharmaceuticals Inc., Princeton, NJ, USA, which also supplied the study drug. Dr Ashrani is a recipient of mentored patient-oriented research career development award (K-23 HL069203) from the National Heart, Lung and Blood Institute, NIH. We would like to thank the research nurse coordinators, Ms Joan Osip at University of Minnesota Medical Center-Fairview, Ms Carol Krasnov at the University of North Carolina, Chapel Hill and Ms Carrie Ma at MD Anderson Cancer Center for their untiring help and support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ashrani, A., Gabriel, D., Gajewski, J. et al. Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplant 38, 825–828 (2006). https://doi.org/10.1038/sj.bmt.1705535
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705535
This article is cited by
-
Current Strategies for Prevention and Management of Stem Cell Transplant-Related Urinary Tract and Voiding Dysfunction
Current Bladder Dysfunction Reports (2015)